{"nctId":"NCT00400946","briefTitle":"Treatment of Acute Lymphoblastic Leukemia in Children","startDateStruct":{"date":"2005-04","type":"ACTUAL"},"conditions":["Drug/Agent Toxicity by Tissue/Organ","Leukemia"],"count":800,"armGroups":[{"label":"Intramuscular native E coli L-asparaginase (IM-EC)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: asparaginase","Drug: cyclophosphamide","Drug: cytarabine","Drug: dexamethasone","Drug: dexrazoxane hydrochloride","Drug: doxorubicin hydrochloride","Drug: etoposide","Drug: leucovorin calcium","Drug: mercaptopurine","Drug: methotrexate","Drug: methylprednisolone","Drug: prednisolone","Drug: therapeutic hydrocortisone","Drug: vincristine sulfate","Radiation: radiation therapy"]},{"label":"Intravenous PEG-asparaginase (IV-PEG)","type":"EXPERIMENTAL","interventionNames":["Drug: cyclophosphamide","Drug: cytarabine","Drug: dexamethasone","Drug: dexrazoxane hydrochloride","Drug: doxorubicin hydrochloride","Drug: etoposide","Drug: leucovorin calcium","Drug: mercaptopurine","Drug: methotrexate","Drug: methylprednisolone","Drug: pegaspargase","Drug: prednisolone","Drug: therapeutic hydrocortisone","Drug: vincristine sulfate","Radiation: radiation therapy"]}],"interventions":[{"name":"asparaginase","otherNames":[]},{"name":"cyclophosphamide","otherNames":[]},{"name":"cytarabine","otherNames":[]},{"name":"dexamethasone","otherNames":[]},{"name":"dexrazoxane hydrochloride","otherNames":[]},{"name":"doxorubicin hydrochloride","otherNames":[]},{"name":"etoposide","otherNames":[]},{"name":"leucovorin calcium","otherNames":[]},{"name":"mercaptopurine","otherNames":[]},{"name":"methotrexate","otherNames":[]},{"name":"methylprednisolone","otherNames":[]},{"name":"pegaspargase","otherNames":[]},{"name":"prednisolone","otherNames":[]},{"name":"therapeutic hydrocortisone","otherNames":[]},{"name":"vincristine sulfate","otherNames":[]},{"name":"radiation therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of acute lymphoblastic leukemia (ALL)\n\n  * No known mature B-cell ALL, defined by the presence of any of the following:\n\n    * Surface immunoglobulin\n    * L3 morphology\n    * t(8;14)(q24;q32)\n    * t(8;22)\n    * t(2;8)\n  * T-cell surface markers and t(8;14)(q24;q11) allowed\n* No secondary ALL\n\nPATIENT CHARACTERISTICS:\n\n* No known HIV positivity\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior therapy except steroids of â‰¤ 1 week in duration and/or emergent radiation therapy to the mediastinum\n\n  * Patients treated with steroids within the past 7 days will not receive steroid prophase during study treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Asparaginase-Related Toxicity Rate","description":"Asparaginase-related toxicity rate is defined as the percentage of patients who experience allergy (all grades), symptomatic pancreatitis (grade 2 or worse), thrombotic or bleeding complications requiring intervention (grade 2 or worse) with treatment attribution of possibly, probably or definite based on CTCAEv3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"5-Year Disease-Free Survival","description":"Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as \\>25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".89","spread":null},{"groupId":"OG001","value":".90","spread":null}]}]}]},{"type":"SECONDARY","title":"Post-Induction Nadir Serum Asparaginase Activity Level","description":"Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.129","spread":"0.108"},{"groupId":"OG001","value":"0.726","spread":"0.322"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.143","spread":"0.131"},{"groupId":"OG001","value":"0.773","spread":"0.231"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.159","spread":"0.161"},{"groupId":"OG001","value":"0.787","spread":"0.303"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.180","spread":"0.261"},{"groupId":"OG001","value":"0.757","spread":"0.255"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.123","spread":"0.102"},{"groupId":"OG001","value":"0.806","spread":"0.313"}]}]}]},{"type":"SECONDARY","title":"Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate","description":"Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Post-Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL ever during post-induction therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Infection Toxicity Rate","description":"Infection toxicity rate is defined as the percentage of patients who experience bacterial or fungal infection of grade 3 or higher with treatment attribution of possibly, probably or definite based on CTCAEv3 during remission induction phase of combination chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Serum Asparaginase Activity Level","description":"Serum asparaginase activity (NSAA) levels were estimated based on established methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".694","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".505","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".048","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Therapeutic Nadir Serum Asparaginase Activity Rate","description":"Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL at a given timepoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"5-Year Disease-Free Survival by MRD Day 32 Status","description":"Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as \\>25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".79","spread":null},{"groupId":"OG001","value":".90","spread":null}]}]}]},{"type":"SECONDARY","title":"5-Year Disease-Free Survival by Bone Marrow Day 18 Status","description":"Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as \\>25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".89","spread":null},{"groupId":"OG001","value":".78","spread":null},{"groupId":"OG002","value":".88","spread":null}]}]}]},{"type":"SECONDARY","title":"5-year Disease-Free Survival by CNS Directed Treatment Group","description":"Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as \\>25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".89","spread":null},{"groupId":"OG001","value":".89","spread":null},{"groupId":"OG002","value":"1.00","spread":null},{"groupId":"OG003","value":".84","spread":null},{"groupId":"OG004","value":".87","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":132,"n":231},"commonTop":["Fracture","Pancreatitis","Osteonecrosis (avascular necrosis)","Hypertension","Allergic reaction"]}}}